Skip to content
HowShorted

TransMedics Group, Inc. short interest in 2023

In 2023, TransMedics Group, Inc.'s disclosed short interest ran from 4.74% of shares outstanding on 13 Jan 2023 to 17.10% on 29 Dec 2023, a change of +12.36 percentage points. The year's high was 19.94% on 31 Oct 2023 and its low 4.14% on 31 Jan 2023, averaging 11.42% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 16.81 days on 29 Dec 2023. Full history: TransMedics Group, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for TransMedics Group, Inc. in 2023

2023 in figures

Start of year
4.74% (13 Jan 2023)
End of year
17.10% (29 Dec 2023)
Change
+12.36 pp
High
19.94% (31 Oct 2023)
Low
4.14% (31 Jan 2023)
Average
11.42%
Highest days to cover
16.81 (29 Dec 2023)
SEC filings marked
8

Every report in 2023

TransMedics Group, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20234.74%5.53
31 Jan 20234.14%3.41
15 Feb 20234.19%3.76
28 Feb 20234.68%1.85results (8-K), 10-K filed
15 Mar 20235.09%3.12
31 Mar 20235.81%5.75
14 Apr 20236.76%4.73
28 Apr 20237.49%3.56
15 May 202310.14%3.15results (8-K), 10-Q filed
31 May 202310.71%7.24
15 Jun 202311.71%5.82
30 Jun 202312.13%9.19
14 Jul 202311.90%9.42
31 Jul 202310.89%9.82
15 Aug 202311.26%2.86results (8-K), 10-Q filed
31 Aug 202312.71%6.53
15 Sep 202314.62%5.96
29 Sep 202315.91%8.74
13 Oct 202317.94%5.65
31 Oct 202319.94%11.89
15 Nov 202319.06%3.39results (8-K), 10-Q filed
30 Nov 202318.09%11.48
15 Dec 202317.12%11.16
29 Dec 202317.10%16.81

See also: TransMedics Group, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.